Gurgel Ricardo G, Bohland Anna K, Vieira Sarah C F, Oliveira Débora M P, Fontes Paula B, Barros Viviane F, Ramos Marcela F, Dove Winifred, Nakagomi Toyoko, Nakagomi Osamu, Correia Jailson B, Cunliffe Nigel, Cuevas Luis E
Federal University of Sergipe, Aracaju, Brazil.
Gastroenterology. 2009 Dec;137(6):1970-5. doi: 10.1053/j.gastro.2009.07.046. Epub 2009 Jul 24.
BACKGROUND & AIMS: Rotavirus vaccines were introduced in Brazil in 2006; we evaluated their effects in the state of Sergipe, Brazil.
We performed a cross-sectional survey of children with diarrhea attending emergency services in Aracaju, Brazil, between October 2006 and April 2008 and a cluster sampling survey to assess vaccination coverage. Vaccine efficacy was assessed using the screening method. Diarrhea consultation and hospitalization data (2003-2007) were obtained from state and national surveillance systems.
Rotavirus was detected in 59 of 534 stool samples (11%) from children attending emergency services. The number of rotavirus-positive samples decreased from 18 of 74 (24%) in 2006 to 31 of 321 (9.5%) in 2007 and 10 of 136 (7.4%) in 2008 (P < .01). Diarrhea severity was greater in children with rotavirus (P < .01) but decreased over time (P < .001). Of the rotaviruses detected, 56 of 59 (95%) were P[4]G2 genotype, 1 was P[4]G-non-typeable (NT), 1 was P[NT]G2, and 1 was P[NT]GNT. Diarrhea consultations decreased from 3020 in 2004 to 604 in 2007; reductions were greatest among children under 5 years old. Diarrhea hospitalizations decreased from 2121 in 2003 to 1176 in 2007. Vaccine coverage was 90.3%. Vaccines were highly effective against the strain P[8]G1; efficacy against P[4]G2 genotype was 89% (95% confidence interval: 0.87-0.92) in Aracaju and 95% in Sergipe.
Since vaccines were introduced in 2006, there has been an overall reduction in diarrhea consultations and hospitalizations in northeast Brazil, with the greatest reductions in young children. This might have resulted from vaccination and improved sanitation. Although a single rotavirus genotype (P[4]G2) was recovered, vaccine efficacy was high against this genotype.
轮状病毒疫苗于2006年在巴西投入使用;我们评估了其在巴西塞尔希培州的效果。
我们对2006年10月至2008年4月期间在巴西阿拉卡茹的急诊服务机构就诊的腹泻儿童进行了横断面调查,并进行了整群抽样调查以评估疫苗接种覆盖率。使用筛查方法评估疫苗效力。腹泻咨询和住院数据(2003 - 2007年)来自州和国家监测系统。
在534份来自急诊服务机构儿童的粪便样本中,59份(11%)检测到轮状病毒。轮状病毒阳性样本数量从2006年74份中的18份(24%)降至2007年321份中的31份(9.5%),2008年136份中的10份(7.4%)(P <.01)。轮状病毒感染儿童的腹泻严重程度更高(P <.01),但随时间下降(P <.001)。在检测到的轮状病毒中,59份中的56份(95%)为P[4]G2基因型,1份为P[